Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06451-6 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Xueqian Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Repressor Proteins, Proto-Oncogene Proteins c-ets, Mutation. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
As a member of the ETS family, ETV6 has been demonstrated to be implicated with the molecular etiology of various hematopoietic diseases. However, the clinical impact of ETV6 mutations (ETV6mut) in acute myeloid leukemia (AML) remains unclear. Hereon, we included 879 consecutive newly diagnosed AML patients in our institution to elucidate the prognostic impact of ETV6 mutation status. In the overall cohort, ETV6mut were found in 24 cases (2.7%) and were associated with lower hemoglobin levels. The predominant common mutation types were missense mutations (15/31, 48.4%) and frameshift mutations (14/31, 45.2%). ETV6 mutations often occurred in conjunction with U2AF1 and ASXL1 mutations. Moreover, ETV6mut was associated with a lower complete remission (CR) rate (45.8% vs. 69.1%, P = 0.015) and shorter OS (P = 0.048) compared to the ETV6 wild-type (ETV6wt) group. Notably, the achievement of CR did not contribute to survival benefit in AML with ETV6mut. In multivariate analysis, ETV6 mutation was shown to be an independent adverse factor for OS in AML patients (HR: 1.72, 95% CI: 1.03-2.89; P = 0.040). Taken together, our study shows a mutational profile of ETV6 in AML and suggests that ETV6 mutations are associated with poor prognosis in AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. drwudepei@163.com.
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. drwudepei@163.com.
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. drwudepei@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Wang, H., Han, H., Qi, J., Yao, Y., Xu, X., Pan, T., Wu, D., & Han, Y. (2025). Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study. Annals of Hematology. https://doi.org/10.1007/s00277-025-06451-6
Vancouver
Li X, Wang H, Han H, Qi J, Yao Y, Xu X, et al. Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study. Annals of Hematology. 2025. doi:10.1007/s00277-025-06451-6
BibTeX
@article{Li2025,
author = {Li, Xueqian and Wang, Hong and Han, Haohao and Qi, Jiaqian and Yao, Yifang and Xu, Xiaoyan and Pan, Tingting and Wu, Depei and Han, Yue},
title = {Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06451-6}
}
EUVIMED